Integrated Genomic Analyses of Ovarian Carcinoma
By D. Bell, A. Berchuck, M. Birrer, Jeremy Chien, D. Cramer, F. Dao, R. Dhir, P. Disaia, H. Gabra, Pat Glenn and 251 more. Nature, 2011
7,559 citations recorded by the source corpus.
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.
Subfields: Cancer Research, Molecular Biology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/2d5b040efec060b33c1c4ef72231655de93398c4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Chuan He
- Matthew Meyerson
- Gad Getz
- M. Lawrence
- Abel Gonzalez-Perez
- Núria López-Bigas
- Trey Ideker
- Peter W. Laird
In Molecular Biology
- Trey Ideker
- Chuan He
- Erik P. Garrison
- Mark Gerstein
- Gabor T. Marth
- Haiyuan Yu
- Bryan T. Harada
- Fiona Cunningham
In Reproductive Medicine
- Abel Gonzalez-Perez
- Núria López-Bigas
- David Tamborero
- E. Lengyel
- C. Sessa
- M. Mirza
- A. González-Martín
Citations in the corpus
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas (2013, background): “TCGA reported homologous recombination defects in approximately 50% of high-grade serous cases (14), but included a wide variety of genomic alterations that we did not assess, including BRCA1 hypermethylation, EMSY amplification or mutation, and RAD51C hypermethylation, which in”
- Using distance covariance for improved variable selection with application to learning genetic risk models (2014, background): “arian cancer data Data description Ovarian cancer is the fifth-leading cause of cancer death among women in the United States; 22,240 new cases and 14,030 deaths were estimated to have occurred in 2013[8, 9]. The standard treatment for high-grade serous ovarian cancer is aggressive surgery followed b”